TELBIVUDINE VERSUS TENOFOVIR-BASED TREATMENT OPTIMISATION STRATEGY IN HBeAg-NEGATIVE CHRONIC HEPATITIS B PATIENTS

Krastev, Z.Kotzev, I.Celen, M. K.McNeeley, D.Hamed, K.2024-04-242024-04-2420150168-82781600-0641https://doi.org/10.1016/S0168-8278(15)30844-8https://hdl.handle.net/11468/1629350th International Liver Congress of the European-Association-for-the-Study-of-the-Liver -- APR 22-26, 2015 -- Vienna, AUSTRIA[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keyword]TELBIVUDINE VERSUS TENOFOVIR-BASED TREATMENT OPTIMISATION STRATEGY IN HBeAg-NEGATIVE CHRONIC HEPATITIS B PATIENTSTELBIVUDINE VERSUS TENOFOVIR-BASED TREATMENT OPTIMISATION STRATEGY IN HBeAg-NEGATIVE CHRONIC HEPATITIS B PATIENTSConference Object62S558S559WOS:00036283060035610.1016/S0168-8278(15)30844-8Q1